Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE
A year after their $66 million launch, the Swiss upstart Pharvaris has managed to convince another fleet of new and returning investors to back …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
